FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1783838151> ?p ?o ?g. }

• W1783838151 endingPage "2461" @default.
• W1783838151 startingPage "2461" @default.
• W1783838151 abstract "To evaluate response and outcome with a front-line intensive multiagent chemotherapy regimen in adults with Burkitt's-type acute lymphoblastic leukemia (B-ALL).From September 1992 to June 1997, 26 consecutive adults with newly diagnosed untreated B-ALL received hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD). Their median age was 58 years (range, 17 to 79 years), and 46% were > or = 60 years. Patients received Hyper-CVAD alternated with courses of high-dose methotrexate and cytarabine. Granulocyte colony-stimulating factor and prophylactic antibiotics were administered for all eight planned courses. CNS prophylaxis alternated intrathecal methotrexate and cytarabine on days 2 and 7 of each course.Complete remission (CR) was obtained in 21 patients (81%). There were five induction deaths (19%). The median time to CR was 22 days (range, 15 to 89 days); 70% achieved CR within 4 weeks. The 3-year survival rate was 49% (+/- 11%); the 3-year continuous CR rate was 61% (+/- 11%). Twelve CR patients (57%) were in continuous CR at a median follow-up of 3+ years (range, 13+ months to 6.5+ years). Characteristics predicting for worse survival were age > or = 60 years, poor performance status, anemia, thrombocytopenia, peripheral blasts, and increased lactate dehydrogenase level. The 3-year survival rate was 77% for 14 patients younger than 60 years and 17% for 12 patients > or = 60 years (P <.01). Regression analysis identified older age, anemia, and presence of peripheral blasts as independent factors associated with shorter survival. Patients could be stratified according to (1) no or one adverse feature, (2) two adverse features, and (3) all adverse features. The 3-year survival rates were 89%, 47%, and 0%, respectively (P <.01).Hyper-CVAD is effective in adult B-ALL. Identification of patients with high risk for relapse and improved methods to detect residual disease may result in risk-oriented approaches." @default.
• W1783838151 created "2016-06-24" @default.
• W1783838151 creator A5006104041 @default.
• W1783838151 creator A5015140142 @default.
• W1783838151 creator A5027575595 @default.
• W1783838151 creator A5027800341 @default.
• W1783838151 creator A5030500582 @default.
• W1783838151 creator A5038307470 @default.
• W1783838151 creator A5041092566 @default.
• W1783838151 creator A5046097970 @default.
• W1783838151 creator A5060386553 @default.
• W1783838151 creator A5067916180 @default.
• W1783838151 creator A5090435894 @default.
• W1783838151 date "1999-08-01" @default.
• W1783838151 modified "2023-10-12" @default.
• W1783838151 title "Hyper-CVAD Program in Burkitt's-Type Adult Acute Lymphoblastic Leukemia" @default.
• W1783838151 cites W1243984806 @default.
• W1783838151 cites W148262973 @default.
• W1783838151 cites W1672417844 @default.
• W1783838151 cites W1775087301 @default.
• W1783838151 cites W1814753114 @default.
• W1783838151 cites W1832431868 @default.
• W1783838151 cites W1834314364 @default.
• W1783838151 cites W1857640920 @default.
• W1783838151 cites W1864995945 @default.
• W1783838151 cites W1902149439 @default.
• W1783838151 cites W1986644250 @default.
• W1783838151 cites W1991161792 @default.
• W1783838151 cites W2010576366 @default.
• W1783838151 cites W2040893788 @default.
• W1783838151 cites W2076426515 @default.
• W1783838151 cites W2094032712 @default.
• W1783838151 cites W2163251241 @default.
• W1783838151 cites W2178439187 @default.
• W1783838151 cites W2336990540 @default.
• W1783838151 cites W3147894994 @default.
• W1783838151 cites W328988336 @default.
• W1783838151 cites W4230048554 @default.
• W1783838151 cites W4233467193 @default.
• W1783838151 cites W4251062918 @default.
• W1783838151 cites W4293241248 @default.
• W1783838151 cites W60055175 @default.
• W1783838151 doi "https://doi.org/10.1200/jco.1999.17.8.2461" @default.
• W1783838151 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10561310" @default.
• W1783838151 hasPublicationYear "1999" @default.
• W1783838151 type Work @default.
• W1783838151 sameAs 1783838151 @default.
• W1783838151 citedByCount "246" @default.
• W1783838151 countsByYear W17838381512012 @default.
• W1783838151 countsByYear W17838381512013 @default.
• W1783838151 countsByYear W17838381512014 @default.
• W1783838151 countsByYear W17838381512015 @default.
• W1783838151 countsByYear W17838381512016 @default.
• W1783838151 countsByYear W17838381512017 @default.
• W1783838151 countsByYear W17838381512018 @default.
• W1783838151 countsByYear W17838381512019 @default.
• W1783838151 countsByYear W17838381512020 @default.
• W1783838151 countsByYear W17838381512021 @default.
• W1783838151 countsByYear W17838381512022 @default.
• W1783838151 countsByYear W17838381512023 @default.
• W1783838151 crossrefType "journal-article" @default.
• W1783838151 hasAuthorship W1783838151A5006104041 @default.
• W1783838151 hasAuthorship W1783838151A5015140142 @default.
• W1783838151 hasAuthorship W1783838151A5027575595 @default.
• W1783838151 hasAuthorship W1783838151A5027800341 @default.
• W1783838151 hasAuthorship W1783838151A5030500582 @default.
• W1783838151 hasAuthorship W1783838151A5038307470 @default.
• W1783838151 hasAuthorship W1783838151A5041092566 @default.
• W1783838151 hasAuthorship W1783838151A5046097970 @default.
• W1783838151 hasAuthorship W1783838151A5060386553 @default.
• W1783838151 hasAuthorship W1783838151A5067916180 @default.
• W1783838151 hasAuthorship W1783838151A5090435894 @default.
• W1783838151 hasConcept C126322002 @default.
• W1783838151 hasConcept C141071460 @default.
• W1783838151 hasConcept C203014093 @default.
• W1783838151 hasConcept C2776090121 @default.
• W1783838151 hasConcept C2776694085 @default.
• W1783838151 hasConcept C2776755627 @default.
• W1783838151 hasConcept C2777478502 @default.
• W1783838151 hasConcept C2778041864 @default.
• W1783838151 hasConcept C2778461978 @default.
• W1783838151 hasConcept C2779429289 @default.
• W1783838151 hasConcept C2781059491 @default.
• W1783838151 hasConcept C2781107101 @default.
• W1783838151 hasConcept C2781413609 @default.
• W1783838151 hasConcept C2909962599 @default.
• W1783838151 hasConcept C71924100 @default.
• W1783838151 hasConcept C8891405 @default.
• W1783838151 hasConcept C90924648 @default.
• W1783838151 hasConceptScore W1783838151C126322002 @default.
• W1783838151 hasConceptScore W1783838151C141071460 @default.
• W1783838151 hasConceptScore W1783838151C203014093 @default.
• W1783838151 hasConceptScore W1783838151C2776090121 @default.
• W1783838151 hasConceptScore W1783838151C2776694085 @default.
• W1783838151 hasConceptScore W1783838151C2776755627 @default.
• W1783838151 hasConceptScore W1783838151C2777478502 @default.
• W1783838151 hasConceptScore W1783838151C2778041864 @default.
• W1783838151 hasConceptScore W1783838151C2778461978 @default.

• next